GSK Claims Patent Office Exceeds Authority In Continuation Applications Rule
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has filed suit against the Patent and Trademark Office to block new rules limiting the number of continuation applications a patent holder can file
You may also be interested in...
Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits
Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits
Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits